MedTrace Logo

Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98

NCT00369850 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 458

Last updated 2012-07-27

No results posted yet for this study

Summary

RATIONALE: Diagnostic procedures, such as bone mineral density testing and x-ray, help measure bone loss in women receiving treatment for breast cancer. The test results may help doctors plan better treatment.

PURPOSE: This phase III trial is studying bone density and bone loss in postmenopausal women with breast cancer receiving treatment in clinical trial IBCSG-1-98.

Conditions

Interventions

OTHER

laboratory biomarker analysis

Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.

PROCEDURE

Dual energy X-ray absorptiometry (DEXA)

Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.

PROCEDURE

Spine X-ray

Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.

Sponsors & Collaborators

  • ETOP IBCSG Partners Foundation

    lead NETWORK

Principal Investigators

  • Stefan Aebi, MD · Insel Gruppe AG, University Hospital Bern

  • Andrea Decensi, MD · European Institute of Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2008-05-31
Completion
2012-01-31

Countries

  • Australia
  • France
  • Italy
  • New Zealand
  • Peru
  • South Africa
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00369850 on ClinicalTrials.gov